However, clinical data indicate that gastric cancer patients with high NKILA expression in tumor-specific CTLs have shorter median overall survival than those with low expression, suggesting that lncRNA-based therapies may exert tumor microenvironment-specific effects and require further profiling for precision application (95). This evidence concerns the gene NKILA and neoplasm.